Drug Profile
Ilomastat - Quick-Med Techologies
Alternative Names: CS 610; Galardin; GM 6001Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator University of Florida
- Developer Arriva Pharmaceuticals; Daiichi Sankyo Inc; Ligand Pharmaceuticals; Quick-Med Technologies
- Class Amides; Antineoplastics; Eye disorder therapies; Indoles; Small molecules
- Mechanism of Action Matrix metalloproteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chemical burns
- Discontinued Cancer; Chronic obstructive pulmonary disease; Corneal ulcer; Diabetic retinopathy
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Chemical-burns in USA (Topical)
- 31 Dec 2009 Ilomastat is still in preclinical trials for Chemical burns in USA
- 07 Apr 2008 Ilomastat is still in Preclinical trials for Chronic obstructive pulmonary disease in USA